Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India

BACKGROUND: Favipiravir, an RNA-dependent RNA polymerase inhibitor (RdRp), is a broad-spectrum oral antiviral agent approved in India under emergency use authorization, for the treatment of mild-to-moderate coronavirus disease (COVID-19). The present study was planned to evaluate the effectiveness a...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Shashank, Vora, Agam, Venugopal, K, Dadhich, Pramod, Daxini, Anil, Bhagat, Sagar, Patil, Saiprasad, Barkate, Hanmant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154000/
https://www.ncbi.nlm.nih.gov/pubmed/35656155
http://dx.doi.org/10.2147/POR.S364066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154000/
https://www.ncbi.nlm.nih.gov/pubmed/35656155
http://dx.doi.org/10.2147/POR.S364066

Ejemplares similares